Sökning: WFRF:(Steg Philippe Gabriel) >
Dabigatran Dual The...
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor : A Pre-Specified Analysis of the RE-DUAL PCI Trial
-
- Nicolau, Jose C. (författare)
- Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Inst Coracao InCor, Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, SP, Brazil.
-
- Bhatt, Deepak L. (författare)
- Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.;Heart & Vasc Ctr, Boston, MA USA.;Harvard Med Sch, Boston, MA 02115 USA.
-
- Hohnloser, Stefan H. (författare)
- Goethe Univ Frankfurt, Frankfurt, Germany.
-
visa fler...
-
- Kimura, Takeshi (författare)
- Kyoto Univ, Kyoto, Japan.
-
- Lip, Gregory Y. H. (författare)
- Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England.;Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England.;Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark.
-
- Miede, Corinna (författare)
- Mainanalyt Ma GmbH, Sulzbach, Taunus, Germany.
-
- Nordaby, Matias (författare)
- Boehringer Ingelheim Int GmbH, Ingelheim, Germany.
-
- Oldgren, Jonas, 1964- (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Steg, Philippe Gabriel (författare)
- Univ Paris, FACT, INSERM, U1148, Paris, France.;Hop Bichat Claude Bernard, AP HP, Paris, France.
-
- ten Berg, Jurrien M. (författare)
- St Antonius Hosp, Nieuwegein, Netherlands.
-
- Godoy, Lucas C. (författare)
- Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Inst Coracao InCor, Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, SP, Brazil.;Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
-
- Cannon, Christopher P. (författare)
- Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.;Heart & Vasc Ctr, Boston, MA USA.;Harvard Med Sch, Boston, MA 02115 USA.
-
visa färre...
-
Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Inst Coracao InCor, Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, SP, Brazil Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.;Heart & Vasc Ctr, Boston, MA USA.;Harvard Med Sch, Boston, MA 02115 USA. (creator_code:org_t)
- 2020-06-19
- 2020
- Engelska.
-
Ingår i: Drugs. - : Springer Nature. - 0012-6667 .- 1179-1950. ; 80:10, s. 995-1005
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and Objective In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using it with dual therapy? Methods The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months). This prespecified subgroup analysis evaluated risks of a first major bleeding event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-cause mortality/thromboembolic event or unplanned revascularization according to baseline use of a proton pump inhibitor. Results Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline. Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interactionpvalues > 0.05). For gastrointestinal bleeding, no interaction was observed between study treatment and proton pump inhibitor use (interactionpvalues 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin triple therapy). Conclusions Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy, regardless of proton pump inhibitor use at baseline, in patients with atrial fibrillation who underwent percutaneous coronary intervention. Risk of the composite efficacy endpoint appeared to be similar for dabigatran dual therapy vs warfarin triple therapy in patients receiving/not receiving a proton pump inhibitor.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Drugs
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Nicolau, Jose C.
-
Bhatt, Deepak L.
-
Hohnloser, Stefa ...
-
Kimura, Takeshi
-
Lip, Gregory Y. ...
-
Miede, Corinna
-
visa fler...
-
Nordaby, Matias
-
Oldgren, Jonas, ...
-
Steg, Philippe G ...
-
ten Berg, Jurrie ...
-
Godoy, Lucas C.
-
Cannon, Christop ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Drugs
- Av lärosätet
-
Uppsala universitet